Research programme: mRNA COVID-2019 vaccines - Providence Therapeutics
Latest Information Update: 28 Sep 2024
At a glance
- Originator Providence Therapeutics
- Developer Providence Therapeutics; University of Toronto
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in COVID-2019-infections(Prevention) in Canada (IM, Injection)
- 05 Aug 2020 Preclinical trials in COVID-2019 infections (Prevention) in Canada, prior August 2020 (IM)
- 05 Aug 2020 Immunogenicity and safety data from a preclinical trial in COVID-2019 infections released by Providence Therapeutics